NGL FINECHEM
Quarterly Results Analysis [Mar2026]
NGL FINECHEM Quarterly Results
| Consolidated | Mar2026 UnAudited |
Dec2025 UnAudited |
Sep2025 UnAudited |
Jun2025 UnAudited |
Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
|---|---|---|---|---|---|---|---|---|
| Revenues | ₹149 Cr | ₹128 Cr | ₹120 Cr | ₹104 Cr | ₹95 Cr | ₹89 Cr | ₹93 Cr | ₹91 Cr |
| Expenses | ₹128 Cr | ₹105 Cr | ₹103 Cr | ₹93 Cr | ₹89 Cr | ₹84 Cr | ₹82 Cr | ₹81 Cr |
| Operating Income | ₹21 Cr | ₹22 Cr | ₹17 Cr | ₹11 Cr | ₹6 Cr | ₹5 Cr | ₹12 Cr | ₹9 Cr |
| Other Income | ₹2 Cr | ₹5 Cr | ₹2 Cr | ₹6 Cr | ₹-1 Cr | ₹0 Cr | ₹5 Cr | ₹6 Cr |
| Interest | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
| Profit Before Tax | ₹18 Cr | ₹21 Cr | ₹13 Cr | ₹12 Cr | ₹1 Cr | ₹1 Cr | ₹13 Cr | ₹12 Cr |
| Profit After Tax | ₹13 Cr | ₹16 Cr | ₹10 Cr | ₹9 Cr | ₹1 Cr | ₹1 Cr | ₹10 Cr | ₹9 Cr |
| EPS | ₹21.83 | ₹25.40 | ₹15.58 | ₹14.96 | ₹0.88 | ₹2.07 | ₹15.88 | ₹14.92 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NGL FINECHEM | -2% | 17.7% | 120.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -3% | -1.9% | 7.5% |
| DIVIS LABORATORIES | -3.3% | -0.7% | -1.6% |
| TORRENT PHARMACEUTICALS | -3.8% | 2.8% | 36.4% |
| CIPLA | -3% | 3% | -6.1% |
| DR REDDYS LABORATORIES | -4.3% | -2% | 2.5% |
| MANKIND PHARMA | -2% | 4.9% | -7.5% |
| LUPIN | -0.7% | -3.8% | 15.9% |
| ZYDUS LIFESCIENCES | -0.9% | 19.4% | 16.5% |
NGL FINECHEM Quarterly Revenues
| Revenues | |
|---|---|
| Q-o-Q | 17.04 % |
| Y-o-Y | 57.14 % |
| Quarters | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹149 Cr | 17.04 | |
| Dec2025 | ₹128 Cr | 6.03 | |
| Sep2025 | ₹120 Cr | 15.43 | |
| Jun2025 | ₹104 Cr | 9.70 | |
| Mar2025 | ₹95 Cr | 6.59 | |
| Dec2024 | ₹89 Cr | -4.69 | |
| Sep2024 | ₹93 Cr | 3.01 | |
| Jun2024 | ₹91 Cr | - | |
NGL FINECHEM Quarterly Operating Profit
| Operating Profit | |
|---|---|
| Q-o-Q | -4.04 % |
| Y-o-Y | 238.87 % |
| Quarters | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹21 Cr | -4.04 | |
| Dec2025 | ₹22 Cr | 30.07 | |
| Sep2025 | ₹17 Cr | 56.33 | |
| Jun2025 | ₹11 Cr | 73.67 | |
| Mar2025 | ₹6 Cr | 23.97 | |
| Dec2024 | ₹5 Cr | -55.90 | |
| Sep2024 | ₹12 Cr | 23.60 | |
| Jun2024 | ₹9 Cr | - | |
| Operating Margins | |
|---|---|
| Q-o-Q | -18.00 % |
| Y-o-Y | 115.79 % |
| Quarters | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 14.35% | -18.00 | |
| Dec2025 | 17.5% | 22.63 | |
| Sep2025 | 14.27% | 35.52 | |
| Jun2025 | 10.53% | 58.35 | |
| Mar2025 | 6.65% | 16.26 | |
| Dec2024 | 5.72% | -53.72 | |
| Sep2024 | 12.36% | 20.00 | |
| Jun2024 | 10.3% | - | |
NGL FINECHEM Quarterly Profit After Tax
| Profit After Tax(PAT) | |
|---|---|
| Q-o-Q | -14.05 % |
| Y-o-Y | 2,383.61 % |
| Quarters | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹13 Cr | -14.05 | |
| Dec2025 | ₹16 Cr | 63.00 | |
| Sep2025 | ₹10 Cr | 4.17 | |
| Jun2025 | ₹9 Cr | 1,601.84 | |
| Mar2025 | ₹1 Cr | -57.51 | |
| Dec2024 | ₹1 Cr | -86.98 | |
| Sep2024 | ₹10 Cr | 6.43 | |
| Jun2024 | ₹9 Cr | - | |
| PAT Margins | |
|---|---|
| Q-o-Q | -26.50 % |
| Y-o-Y | 1,485.96 % |
| Quarters | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 9.04 % | -26.50 | |
| Dec2025 | 12.3 % | 53.75 | |
| Sep2025 | 8 % | -9.81 | |
| Jun2025 | 8.87 % | 1,456.14 | |
| Mar2025 | 0.57 % | -60.14 | |
| Dec2024 | 1.43 % | -86.38 | |
| Sep2024 | 10.5 % | 3.35 | |
| Jun2024 | 10.16 % | - | |
NGL FINECHEM Quarterly Earnings Per Share (EPS)
| EPS | |
|---|---|
| Q-o-Q | -14.06 % |
| Y-o-Y | 2,380.68 % |
| Quarters | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹21.83 | -14.06 | |
| Dec2025 | ₹25.4 | 63.03 | |
| Sep2025 | ₹15.58 | 4.14 | |
| Jun2025 | ₹14.96 | 1,600.00 | |
| Mar2025 | ₹0.88 | -57.49 | |
| Dec2024 | ₹2.07 | -86.96 | |
| Sep2024 | ₹15.88 | 6.43 | |
| Jun2024 | ₹14.92 | - | |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD